Signed Supply Agreement with Chinese Medical Aesthetics Company UPS BIO
Aiming for 30 Billion Won in Sales through Local Distribution Network over Five Years

On June 2, CGBio announced that it has signed a collaboration agreement with Chinese medical aesthetics specialist UPS BIO for the supply of hyaluronic acid (HA) fillers and the launch of a new brand, 'Eloyan.'


At the signing ceremony for the contract between CeCi Biotech and UPS BIO, representatives from both companies are taking a commemorative photo. CeCi Biotech

At the signing ceremony for the contract between CeCi Biotech and UPS BIO, representatives from both companies are taking a commemorative photo. CeCi Biotech

View original image

This agreement introduces a new brand following the existing HA filler brand 'Gisellinew,' which is already active in the Chinese market. It marks the first case of CGBio's multi-brand strategy being fully implemented in China.


The Chinese medical aesthetics market is characterized by diverse consumer preferences depending on region and distribution channel, making market segmentation strategies using multiple brands widely adopted. Based on its operational experience with Gisellinew, CGBio plans to combine its expertise with UPS BIO’s local distribution and marketing capabilities to expand its customer base and sales channels.


UPS BIO is a company with a network of medical aesthetics hospitals in China and strong marketing capabilities based on key opinion leaders (KOLs) in the medical aesthetics field. It is engaged in the brand development and distribution of global aesthetic products.


The product to be supplied under this agreement is CGBio's HA filler, which received approval from the National Medical Products Administration (NMPA) of China in 2019 and has since been sold locally under the Gisellinew brand. With the launch of Eloyan, the company aims to build a brand portfolio tailored to the characteristics of different regions and channels, further strengthening its position in the Chinese market.


Over the next five years, the two companies will work together to expand the HA filler business in the Chinese medical aesthetics market. Their goal is to achieve brand sales of approximately 30 billion won through the local distribution network.



Hyunseung Yoo, CEO of CGBio, stated, "In the Chinese medical aesthetics market, not only product competitiveness but also brand strategy and local partnerships are crucial." He added, "Through our multi-brand strategy, we will build an optimized brand portfolio tailored to the characteristics of each region and channel, thereby strengthening our competitiveness in the Chinese market." He continued, "By cooperating with UPS BIO, we will work to establish our new brand in the market and further enhance our brand competitiveness in the global medical aesthetics sector."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing